{"id":59140,"date":"2026-03-10T13:01:00","date_gmt":"2026-03-10T05:01:00","guid":{"rendered":"https:\/\/flcube.com\/?p=59140"},"modified":"2026-03-10T13:01:01","modified_gmt":"2026-03-10T05:01:01","slug":"merck-kgaa-cuts-springworks-hippo-inhibitor-and-hengrui-parp1-program-rd-pipeline-optimization-ditches-e3-7-billion-in-acquired-assets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59140","title":{"rendered":"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets"},"content":{"rendered":"\n<p><strong>Merck KGaA<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:ETR\">ETR: MRK<\/a>) announced <strong>completion of a new R&amp;D pipeline optimization<\/strong>, <strong>terminating development<\/strong> of <strong>SW-682<\/strong> (Hippo pathway\/TEAD inhibitor) acquired through its <strong>\u20ac2.3\u202fbillion SpringWorks purchase<\/strong> and <strong>ending its partnership<\/strong> on <strong>HRS-1167<\/strong> (PARP1 inhibitor) licensed from <strong>Jiangsu Hengrui Pharmaceuticals<\/strong> in a <strong>\u20ac1.4\u202fbillion deal<\/strong>. The strategic retrenchment, which also discontinues <strong>Ogsiveo exploration in ovarian granulosa cell tumors<\/strong>, signals Merck&#8217;s <strong>sharpened focus on approved Rare Diseases assets<\/strong> over high-risk early-stage oncology bets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-cuts-overview\">Pipeline Cuts Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Origin<\/th><th>Prior Investment<\/th><th>Status<\/th><th>Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>SW-682<\/strong><\/td><td>SpringWorks acquisition (2025)<\/td><td>\u20ac2.3\u202fbn deal (total)<\/td><td><strong>Terminated<\/strong><\/td><td>Pan-TEAD inhibitor (Phase I) removed from active pipeline<\/td><\/tr><tr><td><strong>HRS-1167<\/strong><\/td><td>Hengrui Pharmaceuticals license (2023)<\/td><td>Up to \u20ac1.4\u202fbn<\/td><td><strong>Partnership ended<\/strong><\/td><td>PARP1 inhibitor deprioritized internally<\/td><\/tr><tr><td><strong>Ogsiveo expansion<\/strong><\/td><td>SpringWorks (Ogsiveo approved)<\/td><td>\u2014<\/td><td><strong>Discontinued<\/strong><\/td><td>Ovarian granulosa cell tumor exploration halted<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Total Impacted Value:<\/strong> ~\u20ac3.7\u202fbillion in acquisition\/licensing commitments<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-prioritization\">Strategic Context &amp; Prioritization<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset Category<\/th><th>Decision<\/th><th>Merck Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>SW-682 (Hippo\/TEAD)<\/strong><\/td><td>Termination<\/td><td>SpringWorks acquisition centered on <strong>approved drugs<\/strong> (Ogsiveo, Gomekli); early-stage Hippo inhibitor high-risk, competitive landscape crowded<\/td><\/tr><tr><td><strong>HRS-1167 (PARP1)<\/strong><\/td><td>Partnership exit<\/td><td>Second-gen PARP inhibitors face efficacy\/safety challenges; internal priority lowered amid portfolio review<\/td><\/tr><tr><td><strong>Ogsiveo expansion<\/strong><\/td><td>Indication halt<\/td><td>Ovarian granulosa cell tumor niche insufficient for commercial investment; focus on core desmoid tumor indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Retained SpringWorks Value:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ogsiveo<\/strong> (nirogacestat): Approved for desmoid tumors; revenue-generating<\/li>\n\n\n\n<li><strong>Gomekli\/Ezmekly<\/strong> (mirdametinib): Approved for NF1 plexiform neurofibromas; growth driver<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-market-implications\">Financial &amp; Market Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Write-down Risk<\/strong><\/td><td>Potential impairment charges on SW-682 and HRS-1167 milestones; Q1 2026 earnings impact anticipated<\/td><\/tr><tr><td><strong>R&amp;D Efficiency<\/strong><\/td><td>~15-20% of oncology early-stage budget reallocated to Rare Diseases and core franchises<\/td><\/tr><tr><td><strong>Investor Sentiment<\/strong><\/td><td>Disciplined portfolio management viewed positively; avoids &#8220;throwing good money after bad&#8221;<\/td><\/tr><tr><td><strong>Hengrui Relationship<\/strong><\/td><td>Termination of PARP1 deal may strain future China partnerships; Merck retains other ADC options<\/td><\/tr><tr><td><strong>Competitive Dynamics<\/strong><\/td><td>TEAD inhibitor space (Vivace Therapeutics, iOnctura) loses major pharma entrant; PARP1 field consolidates around AstraZeneca, GSK<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-pipeline-priorities\">Forward-Looking Pipeline Priorities<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Focus<\/th><th>Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>Rare Diseases<\/strong><\/td><td>Ogsiveo, Gomekli commercialization; pimicotinib (TGCT)<\/td><td>Proven revenue; defendable markets<\/td><\/tr><tr><td><strong>Oncology (Late-stage)<\/strong><\/td><td>Bavencio combinations; xevinapant (head\/neck cancer)<\/td><td>Near-term approval potential<\/td><\/tr><tr><td><strong>Immunology<\/strong><\/td><td>Evobrutinib (BTK); talquetamab (GPRC5D)<\/td><td>Differentiated mechanisms<\/td><\/tr><tr><td><strong>Early-stage cuts<\/strong><\/td><td>Hippo, PARP1, Ogsiveo expansion<\/td><td>Resource reallocation to higher-ROI programs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding pipeline prioritization, impairment charges, and strategic focus for Merck KGaA following R&amp;D optimization. Actual results may differ due to competitive dynamics, regulatory requirements for retained assets, and partnership renegotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck KGaA (ETR: MRK) announced completion of a new R&amp;D pipeline optimization, terminating development of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59141,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[1147,2586,120],"class_list":["post-59140","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-etr-mrk","tag-hengrui-pharmaceuticals","tag-merck"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck KGaA (ETR: MRK) announced completion of a new R&amp;D pipeline optimization, terminating development of SW-682 (Hippo pathway\/TEAD inhibitor) acquired through its \u20ac2.3\u202fbillion SpringWorks purchase and ending its partnership on HRS-1167 (PARP1 inhibitor) licensed from Jiangsu Hengrui Pharmaceuticals in a \u20ac1.4\u202fbillion deal. The strategic retrenchment, which also discontinues Ogsiveo exploration in ovarian granulosa cell tumors, signals Merck&#039;s sharpened focus on approved Rare Diseases assets over high-risk early-stage oncology bets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59140\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets\" \/>\n<meta property=\"og:description\" content=\"Merck KGaA (ETR: MRK) announced completion of a new R&amp;D pipeline optimization, terminating development of SW-682 (Hippo pathway\/TEAD inhibitor) acquired through its \u20ac2.3\u202fbillion SpringWorks purchase and ending its partnership on HRS-1167 (PARP1 inhibitor) licensed from Jiangsu Hengrui Pharmaceuticals in a \u20ac1.4\u202fbillion deal. The strategic retrenchment, which also discontinues Ogsiveo exploration in ovarian granulosa cell tumors, signals Merck&#039;s sharpened focus on approved Rare Diseases assets over high-risk early-stage oncology bets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59140\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T05:01:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T05:01:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59140#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59140\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets\",\"datePublished\":\"2026-03-10T05:01:00+00:00\",\"dateModified\":\"2026-03-10T05:01:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59140\"},\"wordCount\":410,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59140#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1001.webp\",\"keywords\":[\"ETR: MRK\",\"Hengrui Pharmaceuticals\",\"Merck\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59140#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59140\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59140\",\"name\":\"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59140#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59140#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1001.webp\",\"datePublished\":\"2026-03-10T05:01:00+00:00\",\"dateModified\":\"2026-03-10T05:01:01+00:00\",\"description\":\"Merck KGaA (ETR: MRK) announced completion of a new R&D pipeline optimization, terminating development of SW-682 (Hippo pathway\\\/TEAD inhibitor) acquired through its \u20ac2.3\u202fbillion SpringWorks purchase and ending its partnership on HRS-1167 (PARP1 inhibitor) licensed from Jiangsu Hengrui Pharmaceuticals in a \u20ac1.4\u202fbillion deal. The strategic retrenchment, which also discontinues Ogsiveo exploration in ovarian granulosa cell tumors, signals Merck's sharpened focus on approved Rare Diseases assets over high-risk early-stage oncology bets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59140#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59140\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59140#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59140#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets - Insight, China&#039;s Pharmaceutical Industry","description":"Merck KGaA (ETR: MRK) announced completion of a new R&D pipeline optimization, terminating development of SW-682 (Hippo pathway\/TEAD inhibitor) acquired through its \u20ac2.3\u202fbillion SpringWorks purchase and ending its partnership on HRS-1167 (PARP1 inhibitor) licensed from Jiangsu Hengrui Pharmaceuticals in a \u20ac1.4\u202fbillion deal. The strategic retrenchment, which also discontinues Ogsiveo exploration in ovarian granulosa cell tumors, signals Merck's sharpened focus on approved Rare Diseases assets over high-risk early-stage oncology bets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59140","og_locale":"en_US","og_type":"article","og_title":"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets","og_description":"Merck KGaA (ETR: MRK) announced completion of a new R&D pipeline optimization, terminating development of SW-682 (Hippo pathway\/TEAD inhibitor) acquired through its \u20ac2.3\u202fbillion SpringWorks purchase and ending its partnership on HRS-1167 (PARP1 inhibitor) licensed from Jiangsu Hengrui Pharmaceuticals in a \u20ac1.4\u202fbillion deal. The strategic retrenchment, which also discontinues Ogsiveo exploration in ovarian granulosa cell tumors, signals Merck's sharpened focus on approved Rare Diseases assets over high-risk early-stage oncology bets.","og_url":"https:\/\/flcube.com\/?p=59140","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-10T05:01:00+00:00","article_modified_time":"2026-03-10T05:01:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59140#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59140"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets","datePublished":"2026-03-10T05:01:00+00:00","dateModified":"2026-03-10T05:01:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59140"},"wordCount":410,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59140#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1001.webp","keywords":["ETR: MRK","Hengrui Pharmaceuticals","Merck"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59140#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59140","url":"https:\/\/flcube.com\/?p=59140","name":"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59140#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59140#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1001.webp","datePublished":"2026-03-10T05:01:00+00:00","dateModified":"2026-03-10T05:01:01+00:00","description":"Merck KGaA (ETR: MRK) announced completion of a new R&D pipeline optimization, terminating development of SW-682 (Hippo pathway\/TEAD inhibitor) acquired through its \u20ac2.3\u202fbillion SpringWorks purchase and ending its partnership on HRS-1167 (PARP1 inhibitor) licensed from Jiangsu Hengrui Pharmaceuticals in a \u20ac1.4\u202fbillion deal. The strategic retrenchment, which also discontinues Ogsiveo exploration in ovarian granulosa cell tumors, signals Merck's sharpened focus on approved Rare Diseases assets over high-risk early-stage oncology bets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59140#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59140"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59140#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1001.webp","width":1080,"height":608,"caption":"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59140#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program \u2013 R&amp;D Pipeline Optimization Ditches \u20ac3.7\u202fBillion in Acquired Assets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59140"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59140\/revisions"}],"predecessor-version":[{"id":59142,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59140\/revisions\/59142"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59141"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}